USPTO serial 79285070
BRIGHT PEAK
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jan 11, 2022
- Examiner
- LAM, HAI-LY HUYNH
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with BRIGHT PEAK?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $548*
Plus Government fees of $650
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
MONICA RIVA TALLEY
Monica Riva Talley Sterne, Kessler, Goldstein & Fox P.L.L.C1100 New York Avenue, N.W.Washington, DC 20005UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the treatment and prevention of cancer, autoimmune diseases, infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs, endocrine diseases, nutritional and metabolic diseases, mental and behavioral disorders, diseases of the nervous system, eye and adnexa, ear and mastoid process disorders, diseases of the circulatory system, respiratory system, and digestive system, skin and subcutaneous tissue disorders, diseases of the musculoskeletal system and connective tissue, diseases of the genitourinary system, disorders and abnormalities relating to pregnancy and childbirth, certain conditions originating in the puerperium and perinatal periods, congenital malformations and deformations, and chromosomal abnormalities; medical and veterinary preparations, namely, recombinant or chemically synthesized and optimized proteins; preparations for destroying vermin; fungicides, herbicides; biotechnological preparations, namely, recombinant or chemically synthesized and optimized proteins for medical use; enzymes for medical use; enzymes for veterinary use; biological and chemical reagents for medical or veterinary use; amino acids for medical use; amino acids for veterinary use; peptides for medical or veterinary use, namely, for the treatment of cancer, autoimmune diseases, infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs, endocrine diseases, nutritional and metabolic diseases, mental and behavioral disorders, diseases of the nervous system, eye and adnexa, ear and mastoid process disorders, diseases of the circulatory system, respiratory system, and digestive system, skin and subcutaneous tissue disorders, diseases of the musculoskeletal system and connective tissue, diseases of the genitourinary system, disorders and abnormalities relating to pregnancy and childbirth, certain conditions originating in the puerperium and perinatal periods, congenital malformations and deformations, and chromosomal abnormalities; proteins for medical or veterinary use, namely, recombinant or chemically synthesized and optimized proteins for detection and treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders, autoimmune diseases, infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs, nutritional diseases, mental and behavioral disorders, diseases of the nervous system, eye and adnexa, ear and mastoid process disorders, diseases of the circulatory system and digestive system, skin and subcutaneous tissue disorders, diseases of the musculoskeletal system and connective tissue, disorders and abnormalities relating to pregnancy and childbirth, certain conditions originating in the puerperium and perinatal periods, congenital malformations and deformations, and chromosomal abnormalities; pharmaceutical preparations for cancer treatment; biopharmaceutical preparations for cancer treatment; pharmaceutical compositions and preparations for cancer prevention and treatment; pharmaceutical preparations for treatment of autoimmune and inflammatory diseases; pharmaceutical preparations for treatment of skin diseases; pharmaceutical preparations for treatment of neurodegenerative, metabolic and ophthalmological diseases | ACTIVE | — |
| 042 | Scientific and technological services, namely, scientific research, scientific analysis, and scientific testing in the field of biotechnology and new product research and design services relating thereto; research and development in the field of biotechnology; consulting services in the field of biotechnology; scientific research services in the field of proteins, peptides and antibodies, and scientific advice relating thereto; scientific research services for medical purposes in the field of cancer and autoimmune diseases and scientific advice relating thereto | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Bright Peak Therapeutics AG
- Other trademarks owned by Bright Peak Therapeutics AG
- Other trademarks owned by Bright Peak Therapeutics AG
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named BRIGHT PEAK
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 18, 2022 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jun 23, 2022 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jun 22, 2022 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Apr 11, 2022 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jan 11, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 4, 2021 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Nov 3, 2021 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Oct 26, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 26, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 13, 2021 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Oct 13, 2021 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Oct 6, 2021 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Oct 6, 2021 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Oct 6, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 17, 2021 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Sep 17, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 24, 2021 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Aug 24, 2021 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Aug 24, 2021 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Aug 24, 2021 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jul 29, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 29, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 27, 2021 | ALIE | ASSIGNED TO LIE | — |
| Jul 22, 2021 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Jul 22, 2021 | EXPI | EX PARTE APPEAL-INSTITUTED | — |
| Jul 22, 2021 | JURT | JURISDICTION RESTORED TO EXAMINING ATTORNEY | — |
| Jul 22, 2021 | EXAF | EXPARTE APPEAL RECEIVED AT TTAB | — |
| Jan 26, 2021 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jan 26, 2021 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jan 26, 2021 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jan 6, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 5, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 5, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 7, 2020 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jul 23, 2020 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jul 23, 2020 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 18, 2020 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 17, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 16, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| May 12, 2020 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| May 8, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 7, 2020 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |